Alcon provides eye care products and vision solutions to improve how people see. It develops and manufactures devices and consumables for eye health, including cataract surgery equipment and intraocular lenses, retinal health therapies, and contact lenses, distributed through eye care professionals, hospitals, and consumers. The products work by supporting eye surgery, protecting and restoring vision, or correcting vision with lens-based options, backed by research and development and a global distribution network. Alcon differentiates itself with a broad, end-to-end portfolio across the eye care continuum, a strong emphasis on research and development, strategic partnerships with healthcare providers, and a commitment to diversity and inclusion. Its goal is to enhance vision and quality of life by delivering reliable, high-quality eye care solutions and advancing the science of eye health.
Work here?Claim your company
Industries
Company Size
10,001+
Company Stage
IPO
Headquarters
Geneva, Switzerland
Founded
1945
See people who can refer or advise you
Help us improve and share your feedback! Did you find this helpful?
Total Funding
$1.1B
Above
Industry Average
Funded Over
2 Rounds
Alcon posts Q3 net sales increase across segments, tightens full-year outlook. Thursday, November 12, 2026 12:27 AM GENEVA, Switzerland - Global eyecare leader Alcon (SIX/NYSE:ALC), reported its financial results for the three and nine month periods ending September 30, 2026. Reported net sales for the third quarter of 2026 were $2.7 billion, an increase of 5 percent on both a reported and constant currency basis versus the third quarter of 2025, while reported net sales for the first nine months of 2026 were $8.2 billion, up 7 percent compared with the first nine months of 2025. Excluding favorable currency impacts of 1 percent, sales were up 6 percent on a constant currency basis. The company also tightened its full-year 2026 guidance. Alcon's Vision Care segment saw growth in both Q3 and over the first nine months of the year, the company reported. Net sales were $1.2 billion in Q3, an increase of 6 percent on both a reported and constant currency basis versus the third quarter of 2025. In the first nine months of 2026, Vision Care net sales were $3.7 billion, an increase of 8 percent on a reported basis and 7 percent on a constant currency basis compared with the first nine months of 2025. Within the Vision Care segment, third quarter contact lenses net sales reached $737 million, an increase of 4 percent or 5 percent on a constant currency basis, while for the first nine months of the year, contact lens sales totaled $2.2 billion, an increase of 5 percent on both a reported and constant currency basis. This growth reflects what the company said was a favorable mix of premium products as well as price increases, particularly in the U.S., and was partially offset by declines in legacy product. "In contact lenses we continue to gain share in the U.S. across both dailies and reusables, supported by the breadth of our Water Innovation's portfolio," Alcon CEO David J. Endicott said on a Wednesday conference call. "The underlying market continues to benefit from premiumization, as consumers move toward daily disposables and specialty lenses." Also within the Vision Care segment, ocular health net sales in the third quarter of 2026 were $500 million, an increase of 8 percent on both a reported and constant currency basis, the company reported. Growth was led by Alcon's portfolio of dry eye products, including Tryptyr and Systane, the company advised, and partially offset by declines in contact lens care. For the first nine months of the year, ocular health net sales were $1.5 billion, an increase of 11 percent. Excluding favorable currency impacts of 1 percent, ocular health net sales increased 10 percent constant currency. Alcon's Surgical segment net sales in Q3 were $1.5 billion, an increase of 4 percent on both a reported and constant currency basis versus the third quarter of 2025, the company reported. However, net sales of implantables were $422 million, a decrease of 2 percent on both a reported and constant currency basis. This reflects a decrease in IOLs of 1 percent constant currency, due to what the company identified as competitive pressures in the U.S. For the first nine months of 2026, the Surgical segment reported sales growth of $4.5 billion, an increase of 7 percent on a reported basis and 6 percent on a constant currency basis versus the first nine months of 2025. IOLs increased 1 percent at constant currency, primarily driven by growth in international markets and strong PanOptix Pro performance, the company advised, partially offset by competitive pressures in the U.S. In addition, there were lower sales in surgical glaucoma, the company noted. Equipment/other net sales were $801 million, an increase of 21 percent year-to-date, while Consumables grew 7 percent to $2.4 billion. "We remain on track for our 2026 objectives with year-to-date sales growth of six percent and double-digit core EPS growth, despite some specific areas of competitive pressure," said Endicott. "We are encouraged by the momentum across our newest products and the strength of our pipeline. The breadth of our portfolio of innovation, together with the recent acquisition of Neurotech, positions us well to drive sustainable long-term growth." Operating income in Q3 was $381 million, compared with $332 million in the prior year period, the company stated. Operating margin was 14.0 percent compared to 12.8 percent in the prior year period and increased 1.2 percentage points on both a reported and constant currency basis. The current year period included tariff refunds of $58 million. Operating income was $684 million compared with $1.0 billion in the prior year period, the company advised. Operating margin was 8.4 percent compared to 13.7 percent in the prior year period and decreased 5.3 percentage points on a reported basis and 5.6 percentage points on a constant currency basis. Net cash flows from operating activities amounted to $1.7 billion for the first nine months of 2026, compared with $1.6 billion in the prior year period, the company stated. Free cash flow was $1.3 billion for the nine months of 2026, compared with $1.2 billion in the prior year period. Alcon also tightened its full-year net sales growth guidance. The company now expects sales to grow 6 percent at constant currency, at the midpoint of its prior 5 percent to 7 percent range. The company said it expects a full-year tariff impact, net of mitigating actions and refunds, of approximately $40 million. Approximately two-thirds of the refund benefit is expected to be reinvested in the business, the company noted.
Alcon shares fall as US implant lens competition and a $58 million tariff refund cloud its third quarter. Key points * Q3 sales rose 5% to $2.72 billion and core diluted EPS rose 15% to $0.91; operating income included a $58 million tariff refund [[1]]. * Implantables sales fell 2% to $422 million as intraocular lens sales dropped on US competitive pressure; contact lens sales rose 4% to $737 million [[1]]. * Alcon narrowed 2026 guidance to about 6% constant-currency sales growth and 12% to 14% core EPS growth; shares were down 4.25% early Wednesday, FinChannel reported [[1]] [[2]]. Alcon shares fell on Wednesday after the eye care group's third-quarter results showed falling sales of lens implants used in cataract surgery and profit helped by a one-off tariff refund [[2]]. The NYSE-listed shares traded at $70.91 at 9:38 a.m. ET, down $3.15 or 4.25% from the previous close, FinChannel reported [[2]]. Sales rose 5% on both a reported and constant-currency basis to $2.72 billion in the quarter, Alcon said on Tuesday, Nov. 10, and core diluted EPS rose 15% to $0.91 [[1]]. Operating income of $381 million included $58 million of tariff refunds, and operating margin rose to 14.0% from 12.8% [[1]] [[2]]. J.P. Morgan analysts estimated that operating profit would have missed expectations by about 9% without the refund, according to FinChannel, citing Reuters [[2]]. Where growth slowed. Surgical sales rose 4% to $1.48 billion, but implantables fell 2% to $422 million [[1]]. Intraocular lens sales dropped 1% at constant currency, which Alcon attributed to US competitive pressure, partly offset by its PanOptix Pro lens and international growth [[1]] [[2]]. Vision Care sales rose 6% to $1.24 billion, with contact lenses up 4% to $737 million and ocular health up 8% to $500 million [[1]]. | Q3, $M | 2026 | 2025 | Change | | Net sales | 2,717 | 2,589 | +5% | | Surgical | 1,480 | 1,420 | +4% | | Implantables | 422 | 432 | -2% | | Contact lenses | 737 | 707 | +4% | | Ocular health | 500 | 462 | +8% | | Core diluted EPS ($) | 0.91 | 0.79 | +15% | Citi said the quarter left uncertainty about Alcon's growth trajectory, FinChannel reported [[2]]. Guidance narrowed. Alcon now expects 2026 sales growth of about 6% at constant currency, versus 5% to 7% in August, and core EPS growth of 12% to 14%, versus 12% to 15% [[1]]. It narrowed its core operating margin improvement to 100 to 150 basis points from 90 to 190 [[1]]. "We remain on track for our 2026 objectives with year-to-date sales growth of six percent," CEO David Endicott said [[1]]. Companies mentioned. At the intersection of AI, tech, and markets. The stories that matter, in one email. Free - unsubscribe anytime.
Alcon expects full-year sales growth of about 6% and double-digit core earnings-per-share growth, it said on its third-quarter earnings call on November 11, 2026. US implantable lens revenue fell 2% as competitors ran product trials. Alcon is launching Vivity Pro and TruPlus to defend its share of the premium cataract surgery market. Its UNITY VCS surgical console was placed in 40% of US teaching hospitals in the past year. Alcon's legacy equipment is in 98% of domestic ophthalmology training centres. The company also bought Neurotech Pharmaceuticals to gain ENCELTO, an implanted cell therapy for Macular Telangiectasia Type 2. It targets about 25,000 diagnosed US patients, with projected peak sales of $250 million to $400 million. Operational savings of $130 million should support margins.
Alcon tops Q3 2026 estimates as revenue rises 2.4% to $2.678B. Revenue of $2.678B vs. $2.683B expected and adjusted EPS of $0.91 vs. $0.89; revenue up 2.4% from a year earlier. Alcon (ALC) topped estimates for the third quarter of 2026. Revenue was $2.678 billion, up 2.4% from a year earlier, in line with the $2.683 billion estimate, and adjusted EPS was $0.91, up 15% from a year earlier, above the $0.89 estimate. Adjusted EPS, up 15% YoY vs. $0.89 estimate Revenue, up 2.4% YoY vs. $2.683B estimate EPS beats in the last 8 reports Q3 2026 scorecard. | Parameters | Expected | Actual | Beat/Miss | | Adjusted EPS | $0.89 | $0.91 | Beat by 2.2% | | Revenue | $2.683B | $2.678B | In line | | Change | YoY | QoQ | | Adjusted EPS | | 15% | | 8.3% | | Revenue | | 2.4% | | 4.0% | By its calculation, adjusted EPS was $0.02 above it. The QoQ column compares with the previous quarter's revenue of $2.790 billion and adjusted EPS of $0.84. The YoY column compares with $2.614 billion and $0.79 in the same quarter a year earlier. Track record. * EPS record. Adjusted EPS beat the estimate in 6 of the last 8 reports, including this one. * Revenue record. Revenue beat the estimate in 3 of the last 8 reports. * Revenue trend. Revenue over the last 5 reports, oldest first: $2.614 billion, $2.636 billion, $2.653 billion, $2.790 billion and $2.678 billion. What to watch. * Next-quarter estimates. Consensus calls for EPS of $0.94 and revenue of $2.85 billion next quarter, based on 4 analysts. * Revenue growth. Whether revenue keeps growing from a year earlier after this quarter's 2.4% increase to $2.678 billion. * Estimate record. Whether Alcon extends a record of beating EPS estimates in 6 of its last 8 reports. * Related coverage. See its reports on Azenta, Rigetti Computing, Silicon Laboratories and Astronics. Sources: Results are from Alcon's Nov. 10, 2026 quarterly report. Estimates are consensus figures. The prior-quarter and year-ago comparison figures are from Alcon's earlier quarterly reports. Items labeled by its calculation are its own arithmetic. This article is informational only and is not investment advice.
Alcon earnings: ALC stock falls 5.7% after hours as outlook narrows. ALC Alcon Inc. 74.06 | -6.91% O 74.72 H 75.71 L 72.21 NEW YORK · 6:25pm ET Alcon earnings for the third quarter beat the consensus estimate on Tuesday, Nov. 10, 2026, but shares of Alcon Inc. (NYSE: ALC) fell 5.7% in after-hours trading. The Swiss eye-care company also tightened its full-year 2026 outlook, trimming the top end of its sales and profit growth ranges. Alcon stock was trading at $70.01 as of 5:59 p.m. ET, according to Robinhood market data, down from a regular-session close of $74.25. The shares had already slipped 1.2% during the regular session from the Monday, Nov. 9, close of $75.14. What Alcon reported after the bell. The company released results shortly after the closing bell, in a press release furnished to the SEC on Form 6-K at 4:31 p.m. ET. Third-quarter net sales rose 5% to $2.717 billion from $2.589 billion a year earlier, and core diluted earnings per share came in at $0.91. Robinhood data showed a consensus estimate of $0.89. The weak spot was implantables, the intraocular lenses used in cataract surgery. That line fell 2% to $422 million, and Alcon said U.S. lens sales faced competitive pressure. Chief Executive David J. Endicott said the company remained on track for its 2026 goals "despite some specific areas of competitive pressure." Alcon earnings by the numbers. * Net sales: $2.717 billion, up 5% on both a reported and constant-currency basis from $2.589 billion in the third quarter of 2025. * Core diluted EPS: $0.91, up from $0.79 a year earlier and above the $0.89 consensus estimate in Robinhood data. Reported diluted EPS was $0.54, compared with $0.48. * Core operating margin: 21.8%, up from 20.2%. The reported operating margin of 14.0% included $58 million in U.S. tariff refunds. * Segment sales: Surgical revenue rose 4% to $1.480 billion. Vision Care rose 6% to $1.237 billion, with ocular health up 8% to $500 million, led by the Tryptyr and Systane dry-eye products. * Shareholder returns: $210 million in share repurchases during the quarter, with about $1.0 billion left on a $1.5 billion authorization. How Alcon changed its 2026 outlook. Alcon tightened all three of its main 2026 targets, which it states in constant currency. In its August outlook, the company had projected sales growth of 5% to 7%. It now expects growth of about 6%, the same midpoint. The company now projects core operating margin expansion of 100 to 150 basis points, compared with 90 to 190 basis points previously. Alcon also narrowed its forecast for core diluted EPS growth to 12% to 14%, from 12% to 15%, removing the top percentage point. The outlook assumes a full-year net tariff impact of about $40 million, and the company said about two-thirds of the third-quarter tariff refund is being reinvested in the business. Alcon also expanded its cost-efficiency program. It now estimates total costs at about $230 million and run-rate savings at about $130 million, up from a prior savings estimate of about $100 million. In October, the company announced the acquisition of Neurotech Pharmaceuticals, a retinal cell-therapy developer. Where Alcon shares stand. The after-hours price leaves the stock about 20% below its 52-week high of $87.64, set on Feb. 26, 2026, and above its 52-week low of $61.84, set on May 11, 2026. Regular-session volume on Nov. 10 was 5.32 million shares, about 2.7 times the 30-day average of 1.95 million. Alcon has a market value of about $36.8 billion, based on Robinhood fundamentals data. Robinhood's earnings calendar lists Feb. 23, 2027, as a tentative, unconfirmed date for Alcon's fourth-quarter report. Market data as of 5:59 p.m. ET on Nov. 10, 2026. This article is for informational purposes only and is not investment advice. More news on: ALC More On This
Find jobs on Simplify and start your career today
Don't see your dream role? Check out thousands of other roles on Simplify.Browse all jobs
Industries
Company Size
10,001+
Company Stage
IPO
Headquarters
Geneva, Switzerland
Founded
1945
Find jobs on Simplify and start your career today
Don't see your dream role? Check out thousands of other roles on Simplify.Browse all jobs